204 related articles for article (PubMed ID: 8086125)
1. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met 30) gene. Pathological and immunohistochemical similarity to human familial amyloidotic polyneuropathy, type I.
Araki S; Yi S; Murakami T; Watanabe S; Ikegawa S; Takahashi K; Yamarnura K
Mol Neurobiol; 1994 Feb; 8(1):15-23. PubMed ID: 8086125
[TBL] [Abstract][Full Text] [Related]
2. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, type I.
Yi S; Takahashi K; Naito M; Tashiro F; Wakasugi S; Maeda S; Shimada K; Yamamura K; Araki S
Am J Pathol; 1991 Feb; 138(2):403-12. PubMed ID: 1992765
[TBL] [Abstract][Full Text] [Related]
3. Comparison of amyloid deposition in two lines of transgenic mouse that model familial amyloidotic polyneuropathy, type I.
Takaoka Y; Tashiro F; Yi S; Maeda S; Shimada K; Takahashi K; Sakaki Y; Yamamura K
Transgenic Res; 1997 Jul; 6(4):261-9. PubMed ID: 9232027
[TBL] [Abstract][Full Text] [Related]
4. Role of serum amyloid P component for systemic amyloidosis in transgenic mice carrying human mutant transthyretin gene.
Tashiro F; Yi S; Wakasugi S; Maeda S; Shimada K; Yamamura K
Gerontology; 1991; 37 Suppl 1():56-62. PubMed ID: 1937069
[TBL] [Abstract][Full Text] [Related]
5. Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy.
Kohno K; Palha JA; Miyakawa K; Saraiva MJ; Ito S; Mabuchi T; Blaner WS; Iijima H; Tsukahara S; Episkopou V; Gottesman ME; Shimada K; Takahashi K; Yamamura K; Maeda S
Am J Pathol; 1997 Apr; 150(4):1497-508. PubMed ID: 9095004
[TBL] [Abstract][Full Text] [Related]
6. Pathology of familial amyloidotic polyneuropathy with TTR met 30 in Kumamoto, Japan.
Araki S; Yi S
Neuropathology; 2000 Sep; 20 Suppl():S47-51. PubMed ID: 11037187
[TBL] [Abstract][Full Text] [Related]
7. Transgenic mouse model of familial amyloidotic polyneuropathy.
Shimada K; Maeda S; Murakami T; Nishiguchi S; Tashiro F; Yi S; Wakasugi S; Takahashi K; Yamamura K
Mol Biol Med; 1989 Aug; 6(4):333-43. PubMed ID: 2560117
[TBL] [Abstract][Full Text] [Related]
8. Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis.
Teng MH; Yin JY; Vidal R; Ghiso J; Kumar A; Rabenou R; Shah A; Jacobson DR; Tagoe C; Gallo G; Buxbaum J
Lab Invest; 2001 Mar; 81(3):385-96. PubMed ID: 11310831
[TBL] [Abstract][Full Text] [Related]
9. Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro.
Sousa MM; Fernandes R; Palha JA; Taboada A; Vieira P; Saraiva MJ
Am J Pathol; 2002 Nov; 161(5):1935-48. PubMed ID: 12414539
[TBL] [Abstract][Full Text] [Related]
10. Effect of serum amyloid P component level on transthyretin-derived amyloid deposition in a transgenic mouse model of familial amyloidotic polyneuropathy.
Murakami T; Yi S; Maeda S; Tashiro F; Yamamura K; Takahashi K; Shimada K; Araki S
Am J Pathol; 1992 Aug; 141(2):451-6. PubMed ID: 1497094
[TBL] [Abstract][Full Text] [Related]
11. Genetic abnormalities and pathogenesis of familial amyloidotic polyneuropathy.
Murakami T; Uchino M; Ando M
Pathol Int; 1995 Jan; 45(1):1-9. PubMed ID: 7704238
[TBL] [Abstract][Full Text] [Related]
12. Familial amyloidotic polyneuropathy: protein aggregation in the peripheral nervous system.
João Saraiva M; Mendes Sousa M; Cardoso I; Fernandes R
J Mol Neurosci; 2004; 23(1-2):35-40. PubMed ID: 15126690
[TBL] [Abstract][Full Text] [Related]
13. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model.
Cardoso I; Saraiva MJ
FASEB J; 2006 Feb; 20(2):234-9. PubMed ID: 16449795
[TBL] [Abstract][Full Text] [Related]
14. [Amyloid neuropathy].
Ikegawa S
Rinsho Shinkeigaku; 1990 Dec; 30(12):1371-3. PubMed ID: 1966018
[TBL] [Abstract][Full Text] [Related]
15. [Analyses of amyloid formation mechanism in familial amyloidotic polyneuropathy and therapeutic trial].
Ando Y
Rinsho Byori; 2000 May; 48(5):425-9. PubMed ID: 10892290
[TBL] [Abstract][Full Text] [Related]
16. Targeted conversion of the transthyretin gene in vitro and in vivo.
Nakamura M; Ando Y; Nagahara S; Sano A; Ochiya T; Maeda S; Kawaji T; Ogawa M; Hirata A; Terazaki H; Haraoka K; Tanihara H; Ueda M; Uchino M; Yamamura K
Gene Ther; 2004 May; 11(10):838-46. PubMed ID: 14961068
[TBL] [Abstract][Full Text] [Related]
17. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models.
Ferreira N; Saraiva MJ; Almeida MR
PLoS One; 2012; 7(1):e29933. PubMed ID: 22253829
[TBL] [Abstract][Full Text] [Related]
18. A case of hereditary amyloidosis transthyretin variant Met 30 with amyloid cardiomyopathy, less polyneuropathy, and the presence of giant cells.
Nakamura Y; Yutani C; Nakazato M; Date Y; Baba T; Goto Y
Pathol Int; 1999 Oct; 49(10):898-902. PubMed ID: 10571824
[TBL] [Abstract][Full Text] [Related]
19. Tissue remodeling after interference RNA mediated knockdown of transthyretin in a familial amyloidotic polyneuropathy mouse model.
Gonçalves NP; Gonçalves P; Magalhães J; Ventosa M; Coelho AV; Saraiva MJ
Neurobiol Aging; 2016 Nov; 47():91-101. PubMed ID: 27568093
[TBL] [Abstract][Full Text] [Related]
20. Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster.
Berg I; Thor S; Hammarström P
Neurodegener Dis; 2009; 6(3):127-38. PubMed ID: 19372706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
